300601.SHE Shenzhen Kangtai Biological Products Co Ltd
- Market cap
- CNY 13.9B
- P/E
- 112.9x
- P/B
- 1.39x
- ROE
- 1.3%
- Dividend yield
- 0.95%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300601.SHE undervalued?
Graham number300601.SHE trades 164.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen Kangtai Biological Products Co Ltd fundamental analysis
No fundamental analysis for Shenzhen Kangtai Biological Products Co Ltd yet.
Shenzhen Kangtai Biological Products Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria…
Full company profileShenzhen Kangtai Biological Products Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen Kangtai Biological Products Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 552M | 1.16B | 2.02B | 1.94B | 2.26B | 3.65B | 3.16B | 3.48B | 2.65B | 2.67B | 2.45B |
| Gross Profit | 433M | 1.00B | 1.82B | 1.77B | 2.01B | 2.50B | 2.38B | 2.82B | 1.95B | 2.00B | 1.74B |
| Operating Income | 85.7M | 242M | 481M | 658M | 775M | 1.45B | -318M | 949M | 181M | 251M | 265M |
| EBITDA | 147M | 298M | 571M | 755M | 868M | 1.90B | -27.7M | 1.26B | 585M | 565M | 223M |
| Net Income | 86.2M | 215M | 436M | 575M | 679M | 1.26B | -133M | 861M | 202M | 70.3M | 127M |
| EPS | 0.10 | 0.22 | 0.44 | 0.56 | 0.63 | 1.14 | -0.12 | 0.77 | 0.18 | 0.06 | 0.11 |
| Balance Sheet | |||||||||||
| Total Assets | 1.60B | 2.21B | 3.34B | 3.95B | 9.58B | 14.1B | 13.8B | 15.1B | 14.6B | 14.1B | 13.9B |
| Total Liabilities | 866M | 1.14B | 1.50B | 1.20B | 2.12B | 4.98B | 4.80B | 5.54B | 4.90B | 4.46B | 4.21B |
| Shareholders' Equity | 735M | 1.07B | 1.84B | 2.75B | 7.46B | 9.17B | 8.99B | 9.54B | 9.66B | 9.63B | 9.69B |
| Cash & Short-term Investments | 138M | 260M | 635M | 505M | 3.04B | 4.28B | 1.46B | 1.30B | 2.61B | 257M | 326M |
| Total Debt | 315M | 247M | 413M | 196M | 79.1M | 2.72B | 2.19B | 2.43B | 1.82B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 78.3M | 154M | 336M | 506M | 440M | 1.65B | 546M | 1.03B | 603M | 636M | - |
| Capital Expenditure | 172M | 190M | 344M | 387M | 1.23B | 2.54B | 1.31B | 718M | 472M | 332M | 416M |
| Free Cash Flow | -93.3M | -35.7M | -7.22M | 119M | -787M | -888M | -765M | 315M | 131M | 304M | -80.7M |
| Ratios | |||||||||||
| ROE | 11.7% | 20.0% | 23.7% | 20.9% | 9.1% | 13.8% | -1.5% | 9.0% | 2.1% | 0.7% | 1.3% |
| ROA | 5.4% | 9.7% | 13.0% | 14.5% | 7.1% | 8.9% | -1.0% | 5.7% | 1.4% | 0.5% | 0.9% |
| Net Profit Margin | 15.6% | 18.5% | 21.6% | 29.6% | 30.0% | 34.6% | -4.2% | 24.8% | 7.6% | 2.6% | 5.2% |
| Debt to Equity | 0.43x | 0.23x | 0.22x | 0.07x | 0.01x | 0.30x | 0.24x | 0.25x | 0.19x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen Kangtai Biological Products Co Ltd dividends
- Dividend yield
- 0.95%
- Forward dividend
- 0.06 CNY
- Payout ratio
- 187.0%
- Ex-dividend date
- Oct 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 132M | 0.12 | 187.0% |
| 2024 | CNY 257M | 0.23 | 127.3% |
| 2023 | CNY 201M | 0.18 | 23.3% |
| 2022 | CNY 622M | 0.56 | - |
| 2021 | CNY 206M | 0.19 | 16.3% |
| 2020 | CNY 207M | 0.19 | 30.5% |
| 2019 | CNY 178M | 0.17 | 31.0% |
| 2018 | CNY 64.1M | 0.06 | 14.7% |
| 2017 | CNY 43.1M | 0.04 | 20.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.6:1 on Jun 2, 2022.
Who owns Shenzhen Kangtai Biological Products Co Ltd
- Insiders 47.77%
- Institutions 6.79%
- Public & others 45.44%
- Shares outstanding 1.12B
- Free float 613M
Shenzhen Kangtai Biological Products Co Ltd company profile
- Company name
- Shenzhen Kangtai Biological Products Co Ltd
- Ticker
- 300601.SHE
- ISIN
- CNE100002Q33
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,957
- Fiscal year end
- December
- Address
- Kangtai Group Building, Shenzhen, China, 518057
- Phone
- 86 755 2698 8558
- Website
- biokangtai.com
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria, tetanus, and acellular pertussis combined vaccine, adsorbed; rabies vaccines (human diploid cell, freeze-dried) for human use; haemophilus influenzae type b conjugate vaccines; measles and rubella combined vaccines (live); SARS-CoV-2 vaccines (vero cell, inactivated); and COVID-19 vaccines (ChAdOx1-S recombinant). It also develops measles, mumps, and rubella vaccines; DTaP-Hib-IPV combined vaccines, 4-valent influenza (split) vaccines, and poliomyelitis vaccines (vero cells, inactivated for the Sabin strain). In addition, the company engages in general and special freight transportation; warehousing services; technology development; import and export of goods and technology; agency import and export; investment in and establishment of pharmaceutical projects and other industries; pharmaceutical technology development, information consulting, and leasing services for self-owned buildings and equipment; wholesale and trade of preventive biological products; technical services; technical consulting and exchange; technology transfer and promotion; and contract manufacturing of pharmaceutical products. It exports its products. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
Shenzhen Kangtai Biological Products Co Ltd management
7- Mr. Xiang MiaoPresident & Non-Independent Director · born 1973
- Mr. Jianying MaChief Financial Officer · born 1979
- Mr. Jiankai LiuVP & Non-Independent Director · born 1970
- Ms. Jin TaoVP & Board Secretary · born 1983
- Mr. Jianhui GanVice President · born 1969
- Mr. Qi Nie XiaoVice President · born 1983
- Cui Dong HuangAccounting Supervisor & Head of Accounting Department